medigraphic.com

2002, Number 2

<< Back Next >>

Arch Cardiol Mex 2002; 72 (2)

How much does the medical treatment of chronic chagasic cardiopathy cost? Direct costs in a cardiology referral center

Vallejo M, Montenegro P, Reyes PA

Language: Spanish
References: 59
Page: 129-137
PDF size: 147.39 Kb.


ABSTRACT

Objective: To estimate health care costs of patients with chronic Chagasic cardiomyopathy (CCC) in a cardiovascular referral center (Instituto Nacional de Cardiología I. Chávez). Material and methods: In a retrospective study, 13 clinical charts of CCC patients treated in the hospital during 1998 were reviewed. Diagnostic and therapeutic procedures and patients admission were identify as well as health care costs, which were drawn from the hospital costs system. Results: 62% of the cases were admitted to the hospital through the out-patient facilities. All the patients had a health care subsidy of 15 to 55% allocated to the institutional budget. Health care costs were calculated for minimal, average, and maximum scenarios, according to the patient’s clinical stage and the price of medical equipment used (low, medium, and high). Most of the health care costs are due to the use of high cost diagnostic equipment (33 a 58%) and hospital stay (including the emergency room) (19 a 28%). Conclusion: This is the first approximation to the economic study of Chagas disease in Mexico, providing foundations for further studies on health economics and quality care of CCC, and suggests that prevention should be enhanced.


REFERENCES

  1. WHO: Control of Chagas’ disease. Report of a WHO Expert Committee. WHO Technical report series No. 811. Ginebra. 1991.

  2. Pinto Días JC: História natural da doença de Chagas. Arq Bras Cardiol 1995; 65: 359-365.

  3. Monteón-Padilla VM, Hernández-Becerril N, Guzmán-Bracho C, Rosales-Encina JL, Reyes-López PA: American Trypanosomiasis (Chagas’ disease) and blood banking in Mexico city: seroprevalence and its potential tranfusional transmission risk. Arch Med Res 1999; 30: 393-398.

  4. Grant IH, Gold JW, Witter M, Tanowotz HB, Nathan C, Mayer K, et al: Transfusion-associated acute Chagas diseases acquired in the United State. Ann Int Med 1989; 111: 849-851.

  5. Nickerson P, Our P, Schruder ML, Sekla L, Johnston JB: Transfusion-associated Trypanosoma cruzi infection in a non-endemic area. Ann Int Med 1989; 111: 851-853.

  6. Schmunis GA: Prevention of transfusional Trypanosoma cruzi infection in Latin America. Mem Inst Oswaldo Cruz 1999 (Suppl I); 94: 93-101.

  7. Chagas C, Villela E: Forma cardiaca de tripanosomiasis americana. Mem Inst Oswaldo Cruz 1922; 16: 5-61.

  8. Mazza S: Responsabilidad de la medicina. Lecciones de la segunda serie, del tercer año, de la cátedra de medicina, profesadas en el Colegio de Francia, por Charles Nicolle. Semana Médica. Arg 1935; 12: 1348. Citado por Siervia Iglesias J. Storino R, Rigon D. Cap 2. Antecedentes históricos en la Enfermedad de Chagas. Eds Storino R, Milei J. Mosby/Doyma. Argentina. 1994: pp 28.

  9. Pinto Días JC: Cardiopatía chagásica: mito y desafío. Arch Inst Cardiol Mex 1990; 60: 119-120.

  10. WHO. Chagas Disease. Wkly Epidem Rec. 1990; 34: 257-264.

  11. Segura EL, Pérez AC, Yanovsky JF, Andrade J, Wynne de Matini GJ: Decrease in the prevalence of infection by trypanosoma cruzi (Chagas disease) in young men of Argentina. Bull Panam Am 1985; 79: 252-264.

  12. OPS. Iniciativa del Cono Sur. II Reunión de la Comisión Intergubernamental para la eliminación de triatoma infestas y la interrupción de la tripanosomiasis americana transfusional. Santa Cruz de la Sierra, Bolivia, 4-6/ octubre/ 1993.

  13. Morel CM: Chagas disease, from discovery to control – and beyond: history, myths and lessons to take home. Mem Inst Oswaldo Cruz 1999 (Suppl I); 94: 3-16.

  14. Días PJC, Schofield CJ: The evolution of Chagas disease (American Trypanosomiasis) control after 90 years since Carlos Chagas discovery. Mem Inst Oswaldo Cruz 1999 (Suppl I); 94: 103-121.

  15. Mazzotti L: Dos casos de enfermedad de Chagas en el estado de Oaxaca. Gac Med Mex 1940; 70: 417-420.

  16. Biagi FF, Arce-Gómez E: Los dos primeros casos de miocarditis chagásica, comprobados en México. Arch Inst Cardiol Mex 1965; 35: 611-623.

  17. Rotberg T, Bassoti RG, Caffroni JV, Gorodezky M, Estandia A: Miocardiopatía chagásica. Presentación de un caso. Arch Inst Cardiol Mex 1976; 46: 336-341.

  18. Marcuschamer JM, Reyes PA: Enfermedad de Chagas en México. Arch Inst Cardiol Mex 1978; 48: 952-966.

  19. Salazar PM, Castrejón J, Rodríguez MH, Tay J: Miocarditis chagásica crónica en México. Prensa Med Mex 1979; 5-6: 115-120.

  20. Tay J, Salazar PM, Bucio MI: La enfermedad de Chagas en la República mexicana. Salud Pública Mex 1980; 22: 409-450.

  21. Salazar-Schettino PM, Haro AI: Dos nuevas localizaciones de transmisores de la enfermedad de Chagas en la República Mexicana. Salud Pública Mex 1983; 25: 77-82.

  22. Velasco-Castrejón O, Guzmán-Bracho C: Importancia de la enfermedad de Chagas en México. Rev Lat Amer Microbiol 1986; 28: 275-283.

  23. Salazar-Schettino PM: Reporte de 3 casos de la enfermedad de Chagas en la fase crónica. Rev Mex Patol 1986; 33: 55-63.

  24. Salazar-Schettino PM, Haro ID, Uribarre V: Chagas’ disease in Mexico. Parasitol Today 1988; 4: 448-451.

  25. Rodas A, Toro S, Ramos A, Monteón VM, Reyes PA: La incidencia de anticuerpos anti-Trypanosoma cruzi en pacientes con miocardiopatía dilatada en el Instituto Nacional de Cardiología “Ignacio Chávez”. Arch Inst Cardiol Mex 1992; 62: 541-545.

  26. Zavala-Castro JE, Gutiérrez-Flota H, Barrera-Pérez MA, Bolio-Solís DJ. Zavala-Velázquez JE: Cardiopatía chagásica detectada en pacientes del Hospital General Regional O’Horan, Mérida, Yucatán, México. Arch Inst Cardiol Mex 1995; 65: 541-545.

  27. Tay J, Scherare H, Sánchez J.T, Robert L: Estado actual de la enfermedad de Chagas en la República Mexicana. Bol Chil Parasitol 1992; 47: 43-53.

  28. Dumonteil Eric: Update on Chagas’ disease in Mexico. Salud Publica Mex 1999; 41: 322-327.

  29. Norma Oficial Mexicana. NOM-EM-001-SSA2-1999, Para la vigilancia, prevención y control de enfermedades transmitidas por vector.

  30. Velasco-Castrejón O, Valdespino JL, Tapia-Conyer R, Salvatierra B, Guzmán-Bracho C, Magos C, et al: Seroepidemiología de la enfermedad de Chagas en México. Salud Pública Mex 1991; 34: 186-196.

  31. Guzmán-Bracho C, García-García L, Floriani-Verdugo J, Guerrero-Martínez S, Torres-Cosme M, Ramírez-Melgar C. et al: Riesgo de transmisión de Trypanosoma cruzi por transfusión de sangre en México. Rev Panam Salud Publica 1998; 4: 94-99.

  32. Oliveira-Filho AM. Cost-efectiveness analysis in Chagas’ disease vector’s control intervention. Mem Inst Oswaldo Cruz 1989; 84 (Suppl IV): 409-417.

  33. Monteón VM, Sosa T, Reyes PA: Serological tests for American Trypanosomiasis. A comparative study. Rev Latinoam Microbiol 1989; 31: 35-38.

  34. Monteón VM, Reyes PA, Rosales-Encina JL: Detección de Trypanosoma cruzi en muestras experimentales por el método de reacción en cadena de la ADN polimerasa. Arch Inst Cardiol Mex 1994; 64: 135-143.

  35. Monteón-Padilla VM, Guzmán-Bracho C, Floriani-Verdugo J, Ramos-Echavarría A, Velasco-Castrejón O, Reyes-López PA: Diagnóstico serológico de la enfermedad de Chagas: autosuficiencia y concordancia interlaboratorios. Salud Publica Mex 1995; 37: 232-235.

  36. Kessner DM, Kalk CE, Singer J: Assessing health quality-The case for traces. NJM 1973; 288: 189-193.

  37. Arredondo A, Lockett LY, de Icaza E: Cost of diseases in Brazil: breast cancer, enteritis, cardiac valve disease and bronchopneumonia. Rev Saúde Púbica 1995; 349: 349-354.

  38. Arredondo A, Damian T: Costos económicos en la producción de servicios de salud: del costo de los insumos al costo de manejo de caso. Salud Pública Mex 1997; 39: 117-124.

  39. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J 1980; 44: 672- 673.

  40. Coura JR, DE Abreu LL, Willcox HP, Petana W: Estudio comparativo controloado com emprego de benznidazole, nifurtimox e placebo, na forma crónica da doenca de Chagas; em uma area de campo com transmissao interrompida. I. Avaliaçao preliminar. Rev Soc Bras Med Trop 1997; 30: 139-144.

  41. Coura JR: Perspectivas actuales del tratamiento específico de la enfermedad de Chagas. Bol Chil Parasitol 1996; 51: 69-75.

  42. Hagar JM, Rahimtoola SH: Chagas’ heart disease in the United States. N Engl J Med 1991; 325: 763-768.

  43. DE Castro SL: The challenge of Chagas’ disease chemotherapy: an update of drugs essayed against Trypanosoma cruzi. Acta Trop 1993; 53: 83-98.

  44. Pinto-Días JC, Rodríguez-Coura J: Clinica e terapeutica de doenca de Chagas. (una aboragem prático para o clínico geral). Rio de Janeiro. Editora Fiocruz 1997: 323-351.

  45. Urbina JA: Parasitological cure of Chagas’ disease: is it possible? Is it relevant? Mem Inst Oswaldo Cruz 1999; 94 (Suppl I): 349-355.

  46. Stoppani AO: Quimioterapia de la enfermedad de Chagas. Medicina (B Aires) 1999; 59 (Suppl 2): 147-165.

  47. Bocchi EA, Bellotti D, Uip D, Kalil J, Higuchi ML, Fiorelli A, et al: Long-term follow-up after heart transplantation in Chagas’ disease. Transplantation Proceedings 1993; 25: 1329-1330.

  48. Kierszenbaum F: Chagas’ disease and the autoimmunity hypothesis. Clin Microbiol Rev 1999; 12: 210-223.

  49. Andrade ZA: Immunopathology of Chagas’ disease. Mem Inst Oswaldo Cruz 1999; 94 (Suppl. I): 71-80.

  50. Moncayo A: Progress toward interruption of transmission of Chagas’ disease. Mem Inst Oswaldo Cruz 1999; 94, (Suppl 1): 401-404.

  51. WHO: Progress towards the elimination of transmission of Chagas’ disease in Latinamerica. World Health Stat Q 1997; 50 (3-4): 198.

  52. Moncayo A: Progress towards the interruption of transmission of Chagas’ disease in the southern countries. Medicina (B Aires) 1999; 59 (Suppl 2): 120-124.

  53. Schofield CJ, Días JC: The southern cone initiative against Chagas’ disease. Adv Parasitol 1999; 42: 1-27.

  54. Harry M, Lema F, Romaña CHA: Chagas’ diseases challenge. Lancet 2000; 355: 236.

  55. Cecere MC, Castañera MB, Canale DM, Chuit R, Gurtler RE: Trypanosoma cruzi infection in Triatoma infestans and other triatomines: long-term effects of a control program in rural Northwestern Argentina. Rev Panam Salud Publica 1999; 5: 392-399.

  56. Rojas-de-Arias A, Ferro EA, Ferreira ME, Simancas LC: Chagas’ disease vector control through different intervention modalities in endemic localities of Paraguay. Bull WHO 1999; 77: 331-339.

  57. Schofield CJ, Días JC: A cost-benefit analysis of Chagas’ disease control. Mem Inst Oswaldo Cruz 1991; 86: 285-95.

  58. Guhl F, Vallejo GA. Interruption of Chagas’ disease transmission in the Andean Countries: Colombia. Mem Inst Oswaldo Cruz. 1999; 94(Suppl I): 413-15.

  59. Ponce C: Elimination of the vectorial transmission of Chagas’ disease in Central American Countries: Honduras. Mem Inst Oswaldo Cruz. 1999; 94(Suppl I): 417-18.




2020     |     www.medigraphic.com